8-K: CytoSorbents Faces Nasdaq Delisting Warning

CytoSorbents Corporation received a notice from Nasdaq regarding non-compliance with the minimum bid price requirement, risking its listing.

Summary

• CytoSorbents Corporation received a written notice from the Nasdaq Stock Market LLC on October 2, 2025.
• The notice indicates non-compliance with Nasdaq Listing Rule 5550(a)(2) because the company's common stock had fallen below $1.00 per share for 30 consecutive business days.
• This notification has no immediate effect on the listing or trading of the company's common stock.
• The company has 180 calendar days, until March 31, 2026 (the Compliance Date), to regain compliance with the Minimum Bid Price Requirement.
• To regain compliance, the closing bid price of the common stock must meet or exceed $1.00 per share for a minimum of 10 consecutive business days prior to the Compliance Date.
• If compliance is not regained by the Compliance Date, the company may be eligible for an additional 180-day compliance period if it presents an acceptable plan to Nasdaq.

Sentiment

Score: 3

Explanation: The filing indicates a significant negative event with the Nasdaq non-compliance notice, posing a risk of delisting. While there's a compliance period, the underlying issue of a sustained low stock price is concerning and reflects poor market sentiment.

Negatives

• Received a formal notice of non-compliance from Nasdaq for failing to meet the minimum bid price requirement ($1.00 per share).
• The company's common stock traded below $1.00 for 30 consecutive business days, indicating sustained low market valuation.
• Faces a risk of delisting from The Nasdaq Stock Market LLC if compliance is not regained within the specified period.

Risks

• There is no assurance that the company will be able to regain compliance with the Minimum Bid Price Requirement.
• There is no assurance that the company will otherwise be in compliance with other Nasdaq listing standards.

Future Outlook

The company intends to actively monitor the closing bid price of its common stock and will consider its options to regain compliance with the Minimum Bid Price Requirement.

Management Comments

• CytoSorbents Corporation intends to actively monitor the closing bid price of its common stock and will consider its options to regain compliance with the Minimum Bid Price Requirement.

Industry Context

Companies listed on major exchanges like Nasdaq are required to maintain certain listing standards, including a minimum share price. Falling below this threshold is a common issue for smaller or struggling companies and can lead to reduced investor confidence, liquidity, and potentially a move to an over-the-counter market.

Stakeholder Impact

• Shareholders: Potential loss of liquidity and investor confidence if delisted, possible further stock price decline, and increased volatility.
• Company Reputation: Negative impact on corporate image, potentially hindering future capital raises or business partnerships.

Next Steps

• Actively monitor the closing bid price of its common stock.
• Consider options to regain compliance with the Minimum Bid Price Requirement.
• Potentially present an acceptable plan to Nasdaq for an additional compliance period if compliance is not met by the initial deadline.

Key Dates

Recommendation

The Nasdaq delisting notice signals significant underlying issues with the company's market valuation and investor confidence. A sustained stock price below $1.00 indicates a lack of market support. While a compliance period exists, the risk of delisting and the associated negative impacts on liquidity and reputation are substantial. A seasoned investor would likely consider selling to mitigate further potential losses and avoid the uncertainty of a potential delisting.

Keywords

CytoSorbents Corporation, CTSO, Nasdaq, delisting notice, minimum bid price, stock compliance, SEC filing, 8-K